Fig 3. Lifetime risk of low to intermediate-risk prostate cancer diagnosis (in blue), and high risk or metastatic prostate cancer (in red) under three levels of diagnostic activity: Low as in Sweden 1992; Intermediate as in Sweden 2016; High as in Stockholm 2014; when the Stockholm-3 study invited men to measure their PSA [15].
